New Trial Launches to Address Long COVID
Hyundai Bioscience is making a significant move to tackle Long COVID by joining forces with the University of California San Diego (UCSD) for an investigator-initiated trial. This partnership aims to assess the effectiveness of Xafty, a new antiviral derived from niclosamide and developed at Hyundai’s headquarters in Korea. Leading the trial is Dr. Ajay Bharti, a clinical trial expert well-versed in infectious diseases and the neurocognitive effects of viral infections.
The Challenge of Long COVID
Long COVID affects millions around the world, presenting a range of serious symptoms like chronic fatigue, inflammation, and cognitive decline. Current treatments are mostly limited and tend to focus on specific aspects of this complex condition. Dr. Davey Smith, Director of UCSD's Altman Clinical and Translational Research Institute, highlights the pressing need for effective therapies for this syndrome, as reliable treatments are still lacking.
Xafty’s Potential
Xafty has emerged as a promising oral antiviral that boosts the bioavailability of niclosamide, which is known for its antiviral properties against more than 30 viruses. Currently, Xafty is undergoing phase 3 clinical trials in Korea with a focus on high-risk groups, showing promise in resolving symptoms faster than existing therapies. The drug is also expected to apply for phase 3 trials with the U.S. FDA soon, underscoring its potential role in battling COVID-19 and its long-term effects.
Innovative Mechanism to Alleviate Symptoms
Xafty aims to tackle the unique challenges of Long COVID by providing solutions that go beyond simple viral suppression. It focuses on reducing inflammation and protecting nerve cells. With niclosamide as its active ingredient, this treatment could aid recovery on multiple fronts. Unlike conventional therapies that target just one part of the illness, Xafty’s multifaceted approach could transform current treatment methods.
Recent Research Findings
Hyundai Bioscience's recent studies have shown strong evidence of Xafty’s neuroprotective effects. In studies involving Parkinson's disease, animals treated with Xafty displayed better dopamine production and nerve cell recovery than those receiving standard treatments. This significant discovery suggests that Xafty could effectively address cognitive issues like brain fog, a commonly reported symptom in Long COVID sufferers.
Hopes for Innovative Treatment
Dr. Ajay Bharti expressed his excitement about using Xafty to fight Long COVID. After observing encouraging results in COVID-19 trials, he is hopeful that Xafty’s benefits in neuroprotection could lead to noticeable improvements in the quality of life for patients grappling with complicated Long COVID symptoms. The strong data from previous trials adds to the optimism for viable solutions.
Looking Ahead: The Future of Long COVID Treatments
Hyundai Bioscience believes that proving Xafty’s ability to address the varied symptoms of Long COVID could be revolutionary. If the trial proves successful, it could not only open doors to a new treatment option but also set a historical milestone in understanding and managing Long COVID. They aspire to deliver comprehensive therapeutic solutions that recognize the intricate nature of this syndrome.
About Hyundai Bioscience
Founded in 2000, Hyundai Bioscience specializes in drug development using advanced delivery systems aimed at effectively delivering therapeutic agents. The company is dedicated to repurposing existing medications to broaden their applications and enhance health outcomes for various conditions. Publicly traded on KOSDAQ under the symbol 048410, Hyundai Bioscience is focused on innovation in biotechnology to improve global health outcomes.
Frequently Asked Questions
What’s the main objective of the trial involving Xafty?
The trial primarily aims to assess Xafty’s effectiveness in treating Long COVID symptoms, particularly those complicated conditions associated with the syndrome.
Who leads the investigative trial for Xafty?
The trial is led by Dr. Ajay Bharti, an expert in infectious diseases, at UCSD, utilizing his extensive clinical trial experience.
How is Xafty different from current Long COVID treatments?
Xafty employs a multi-pronged strategy, addressing inflammation and neuroprotection in addition to viral suppression, which many traditional treatments lack.
What previous studies support Xafty’s use?
Studies conducted on Parkinson's disease indicated that Xafty could boost dopamine production and nerve recovery, suggesting potential benefits for Long COVID patients.
What’s Hyundai Bioscience focused on in drug development?
Hyundai Bioscience is committed to innovating drug delivery systems that refine the therapeutic impact of current medications, aiming to improve patient health outcomes.
